Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 37Bevacizumab 34Carboplatin 30pembrolizumab 25Specimen Handling 21Magnetic Resonance Spectroscopy 19olaparib 18Cisplatin 15liposomal doxorubicin 13Taxes 13Immunoglobulin G 12Gemcitabine 12Disulfides 12Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 9mirvetuximab soravtansine 7Doxorubicin 7fludarabine 6Radiation 6Fulvestrant 6niraparib 5durvalumab 5cediranib 5atezolizumab 5Platinum 5Oxaliplatin 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CX 5461 × Gynecologic × 30 days × Clear all
NCT04890613 2026-06-08

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡